Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tipranavir disodium
Drug ID BADD_D02227
Description Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.
Indications and Usage For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
Marketing Status approved; investigational
ATC Code J05AE09
DrugBank ID DB00932
KEGG ID D03843
MeSH ID C107201
PubChem ID 163296
TTD Drug ID D0EV6T
NDC Product Code 0597-0003; 11014-0046; 12714-901
UNII 9BAN2XG1ZW
Synonyms tipranavir | tipranavir, (R-(R*,R*))-isomer | 3'-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2h-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide | Aptivus | tipranavir, (S-(R*,R*))-isomer | tipranavir, (S-(R*,S*))-isomer | tipranavir glucuronide | (2R)-3,6-Dihydro-6-oxo-2-(2-phenylethyl)-2-propyl-5-((1R)-1-(3-(((5-(trifluoromethyl)-2-pyridinyl)sulfonyl)amino)phenyl)propyl)-2H-pyran-4-yl beta-D-glucopyranosiduronic acid | tipranavir, (R-(R*,S*))-isomer | tipranavir C-14 | C14-tipranavir | 14C-tipranavir | tipranavir disodium | PNU-140690E | tipranavir sodium | PNU 140690 | PNU-140690
Chemical Information
Molecular Formula C31H31F3N2Na2O5S
CAS Registry Number 191150-83-1
SMILES CCCC1(CC(=C(C(=O)O1)C(CC)C2=CC(=CC=C2)[N-]S(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)[O-])CC C4=CC=CC=C4.[Na+].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.004--
Rash papular23.03.13.017--Not Available
Renal failure20.01.03.005--Not Available
Retching07.01.07.002--Not Available
Rhabdomyolysis15.05.05.002--
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome10.01.01.045; 12.03.01.014; 23.03.01.007; 11.07.01.005--
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
White blood cell count decreased13.01.06.012--
Cytomegalovirus chorioretinitis11.05.01.006; 06.04.06.009--Not Available
Lipodystrophy acquired14.08.04.008; 23.07.01.003--Not Available
Lymphatic disorder01.09.01.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Mitochondrial toxicity14.11.02.001; 12.03.01.009--Not Available
Transaminases increased13.03.04.036--Not Available
Haemorrhage24.07.01.002--Not Available
Facial wasting14.08.04.004; 23.07.01.004--Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages